The Childhood Version of Cachexia Delivers Lasting Impacts
We’ve written about the significant toll cachexia can take on adults. But the life-threatening syndrome, characterized by the progressive loss of muscle mass and fat, can have a far more pronounced impact on children.
Cachexia, often called “failure to thrive” in children, is associated with chronic illnesses such as cancer. But even if the underlying condition is cured, there can be significant and lasting implications for kids related to physical, cognitive, and emotional development.
As Endevica Bio continues to develop a promising treatment for cachexia, we are cognizant that children are among the many victims of this syndrome whose lives could profoundly benefit from a cure. We are hopeful that our drug will forestall the suffering brought by cachexia – to those of every age group.
That said, children will be among the most significant beneficiaries of a successful treatment. The prevalence of cachexia in children varies depending on the underlying condition. In children with cancer, a significant proportion experience cachexia, particularly those with advanced or recurrent disease. While the exact figures are difficult to pinpoint due to varying diagnostic criteria and limited research, studies suggest that cachexia can affect a substantial number of children facing serious illnesses.
The consequences of cachexia in children are far-reaching. Stunted linear growth is a common outcome, impacting physical development and long-term health. Muscle wasting can lead to weakness, fatigue, and difficulty with daily activities, affecting a child’s ability to play, learn, and socialize.
Cachexia also can have a profound impact on brain development. Malnutrition and inflammation associated with cachexia can disrupt brain function, affecting cognitive development, learning abilities, and emotional well-being. Children who experience cachexia may face challenges with attention, memory, and executive function, impacting their academic performance and overall quality of life. Although children are generally resilient, these cognitive deficits are difficult to reverse once they occur.
The burden of cachexia extends beyond the child to their families. Parents often feel helpless and distressed as they watch their child deteriorate, despite their best efforts to provide adequate nutrition and support. They may experience feelings of guilt, frustration, and inadequacy, often blaming themselves. This can be magnified by well-meaning friends and family members who offer advice on nutrition without understanding the underlying pathology of this condition.
We’re hoping all of this suffering – among the victims and their caregivers – will come to an end with an effective treatment.
By Dr. Daniel Marks, MD, PhD is Chief Medical and Scientific Officer at Endevica Bio.
